Drug Trial Radar · NCT06860243
A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)
Last checked: Nov 19, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
May 13, 2025
Primary completion
Feb 9, 2026
Study completion Feb 19, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Mar 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic \[PK\] study). Researchers will compare what happens to opevesostat in the body when it is given to healthy participants and participants with moderate hepatic (liver) impairment.
Conditions
- Hepatic Impairment
- Healthy Participants
Interventions
OpevesostatDrug
Oral film-coated tablet
PrednisoneDrug
Oral tablet
Fludrocortisone acetateDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Concentration Versus Time Curve from 0 to Infinity (AUC0-inf) of OpevesestatTime frame: At designated timepoints (up to approximately 96 hours post-dose)
- Area Under the Concentration Versus Time Curve from 0 to the Last Quantifiable Sample (AUC0-last) of OpevesestatTime frame: At designated timepoints (up to approximately 96 hours post-dose)
- Area Under the Concentration Versus Time Curve from 0 to 24 hours (AUC0-24) of OpevesestatTime frame: At designated timepoints (up to approximately 24 hours post-dose)
- Maximum Observed Concentration (Cmax) of OpevesestatTime frame: At designated timepoints (up to approximately 96 hours post-dose)
- Time to Maximum Concentration (Tmax) of OpevesestatTime frame: At designated timepoints (up to approximately 96 hours post-dose)
- Apparent Terminal Half-life (t1/2) of OpevesestatTime frame: At designated timepoints (up to approximately 96 hours post-dose)
- Apparent Clearance (CL/F) of OpevesestatTime frame: At designated timepoints (up to approximately 96 hours post-dose)
- Apparent Volume of Distribution During Terminal Phase (Vz/F) of OpevesestatTime frame: At designated timepoints (up to approximately 96 hours post-dose)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Clinical Pharmacology of Miami ( Site 0002)
Miami, Florida
Texas Liver Institute ( Site 0001)
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.